AZ 268888 Dominica
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
- Sex at Birth: Any
- Age: Child (Birth - 17)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Asthma
Study Purpose
Asthma is a lung disease associated with inflammation (swelling) of the air passages. An increase in the number of eosinophils is related to severe asthma. Eosinophils are a type of white blood cell. Benralizumab works by depleting the number of eosinophils, which can help control asthma symptoms. Benralizumab may help decrease inflammation in the air passages of people with asthma. We are doing this study to learn more about benralizumab (the drug that will be tested in this study) to find out if it may result in an improvement of severe eosinophilic asthma and associated health problems.
Who Can Participate
Age: 6-18
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001868
- StudyID: 2022-01076
- ClinicalTrials.gov: N/A
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422